Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1698587

Cover Image

PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1698587

Intravenous Solutions Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

PUBLISHED:
PAGES: 132 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4850
PDF & Excel (Multi User License)
USD 6050
PDF & Excel (Enterprise User License)
USD 8350

Add to Cart

The Global Intravenous Solutions Market, valued at USD 13.9 billion in 2024, is projected to expand at a CAGR of 8% from 2025 to 2034. Intravenous (IV) solutions are sterile liquids administered directly into a patient's bloodstream to maintain hydration, deliver medications, and supply essential nutrients. Demand for IV solutions is rising due to increasing malnutrition, the prevalence of chronic diseases, and food insecurity. A significant portion of the global population struggles with inadequate nutrition, fueling the need for IV solutions. Additionally, the growing use of IV fluids in neonatal and pediatric care is linked to the high incidence of preterm births, which require specialized nutritional support. Hospitals and healthcare facilities worldwide continue to integrate IV solutions into patient care for hydration therapy, nutrient replenishment, and post-surgical recovery.

Intravenous Solutions Market - IMG1

The market is divided by type into total parenteral nutrition and peripheral parenteral nutrition (PPN). In 2024, the PPN segment dominated the market, reaching USD 8.4 billion in revenue. PPN is a preferred method for short-term nutritional support, supplying vital nutrients such as dextrose, amino acids, and lipids through peripheral veins. It helps maintain nutritional balance, prevents deficiencies, and supports patients with limited oral intake. Research suggests that timely PPN administration reduces the risk of infections and metabolic complications, making it a crucial component in modern medical treatments.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$13.9 Billion
Forecast Value$29.6 Billion
CAGR8%

Segmented by composition, the market includes vitamins and minerals, carbohydrates, single-dose amino acids, parenteral lipid emulsions, and other essential compounds. The carbohydrates segment accounted for 40.6% of total market revenue in 2024 and is expected to reach USD 12.2 billion by 2034. Dextrose-based IV solutions are widely used to provide caloric support to critically ill patients who cannot receive nutrition through conventional means. These solutions play a key role in maintaining metabolic stability, preventing muscle breakdown, and aiding recovery. Clinical studies support the effectiveness of carbohydrate-based IV solutions in improving patient outcomes, especially in postoperative and trauma care.

By age group, the geriatric population accounted for the highest market share, representing 48.8% of total revenue in 2024. Older adults are highly susceptible to dehydration due to reduced thirst sensation, mobility challenges, and various health conditions. IV solutions ensure effective hydration and nutrient delivery, preventing complications linked to chronic illnesses. The aging global population further drives demand, with healthcare providers increasingly relying on IV therapy for elderly patients with swallowing difficulties or gastrointestinal disorders.

In terms of application, the market is segmented into nutritional support, blood transfusion, and fluid and electrolyte balance. The nutritional support segment led the market in 2024, generating USD 6.2 billion in revenue. The rising incidence of malnutrition, chronic diseases, and post-surgical recovery needs, contribute to this growth. Patients with gastrointestinal disorders or conditions affecting nutrient absorption benefit significantly from IV-administered nutrition, ensuring adequate nourishment for recovery.

By end use, hospitals and clinics dominated the market, holding a 58.8% revenue share in 2024. These facilities rely heavily on IV solutions for critical care, surgeries, trauma management, and hydration therapy. The increasing prevalence of chronic diseases and advancements in healthcare infrastructure further boost adoption. Additionally, clinics have expanded their use of IV therapy for managing chronic conditions and short-term treatments.

In North America, the intravenous solutions market is witnessing rapid expansion, with the US projected to reach USD 10.6 billion by 2034. Rising healthcare demands, stringent FDA regulations ensuring product quality, and high adoption rates of advanced IV solutions contribute to market growth. With ongoing advancements and increasing awareness of IV therapy's benefits, the market is poised for significant expansion in the coming years.

Product Code: 8359

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 3600 Synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Growing cases of malnutrition
      • 3.2.1.2 High prevalence of pre-term births
      • 3.2.1.3 Increasing prevalence of diseases, such as gastrointestinal disorder, neurological diseases, and cancer
      • 3.2.1.4 Increasing number of surgical procedures
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Stringent regulatory and quality requirements
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Future market trends
  • 3.6 Gap analysis
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Total parenteral nutrition
  • 5.3 Peripheral parenteral nutrition

Chapter 6 Market Estimates and Forecast, By Composition, 2021 – 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Carbohydrates
  • 6.3 Vitamins and minerals
  • 6.4 Single-dose amino acids
  • 6.5 Parenteral lipid emulsion
  • 6.6 Other compositions

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 – 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Pediatric
  • 7.3 Adults
  • 7.4 Geriatric

Chapter 8 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Nutritional support
  • 8.3 Blood transfusion
  • 8.4 Fluid and electrolyte balance
  • 8.5 Other applications

Chapter 9 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 Hospitals and clinics
  • 9.3 Ambulatory surgery centers
  • 9.4 Home care settings

Chapter 10 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Spain
    • 10.3.5 Italy
    • 10.3.6 Netherlands
  • 10.4 Asia Pacific
    • 10.4.1 China
    • 10.4.2 India
    • 10.4.3 Japan
    • 10.4.4 Australia
    • 10.4.5 South Korea
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Argentina
  • 10.6 Middle East and Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 South Africa
    • 10.6.3 UAE

Chapter 11 Company Profiles

  • 11.1 AdvaCare Pharma
  • 11.2 Amanta Healthcare
  • 11.3 Axa Parenterals
  • 11.4 B. Braun
  • 11.5 Baxter International
  • 11.6 Fresenius Kabi
  • 11.7 Grifols
  • 11.8 ICU Medical
  • 11.9 JW Life Science
  • 11.10 Otsuka Pharmaceutical
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!